What GHRP-6 is
GHRP-6 is a ghrelin receptor agonist associated with growth hormone release and appetite-axis effects.
GHRP-6 is grouped under Fitness + Recovery on PeptideFactCheck because it is frequently discussed as a legacy growth hormone secretagogue with appetite-related tradeoffs.
The useful starting point is to separate the molecule itself from the internet story around it. It is commonly described as the secretagogue that can make hunger more noticeable.
Why people keep looking it up
People associate GHRP-6 with GH release and appetite stimulation.
It activates ghrelin receptor signaling, which overlaps with both growth hormone and appetite biology.
GHRP-6 tends to stay in the conversation because it touches a familiar public theme: ghrelin receptor, gh secretagogue, and appetite. That makes it easy for the claim to travel faster than the evidence.
What the evidence can support right now
Hormone-marker evidence does not prove broad recovery, muscle, or longevity outcomes.
Human endocrine data supports GH-release activity, but outcomes beyond that require tighter evidence.
The mechanism is consistent with ghrelin receptor activity and endocrine signaling.
Why this page carries the current tier: Human hormone response data exists, but performance claims need separation from endocrine markers.
The current seed trail for GHRP-6 is pulling from 1 literature source, 1 trials source, and 1 databases source.
Safety, limits, and regulatory context
Appetite stimulation, endocrine spillover, glucose effects, and product-quality issues are common concerns.
No FDA-approved GHRP-6 drug product is listed in this V1 source trail.
Editorial boundary: PeptideFactCheck does not publish dosing, cycling, sourcing, injection, or administration instructions for GHRP-6. The job here is to explain the public claim, the mechanism story, the evidence strength, and the current limits.
Molecular and identifier data
The current PubChem match for GHRP-6 is CID 4345065. That gives the page a source-backed chemistry record rather than a placeholder identifier block.
- PubChem CID
- 4345065
- Formula
- C46H56N12O6
- Molecular weight
- 873.0
- InChIKey
- WZHKXNSOCOQYQX-UHFFFAOYSA-N
Matched synonyms include Ghrp-6, 6-amino-2-[[2-[[2-[2-[[2-[[2-amino-3-(3H-imidazol-4-yl)propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoylamino]-3-(1H-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide, 6-amino-2-((2-((2-(2-((2-((2-amino-3-(3H-imidazol-4-yl)propanoyl)amino)-3-(1H-indol-3-yl)propanoyl)amino)propanoylamino)-3-(1H-indol-3-yl)propanoyl)amino)-3-phenylpropanoyl)amino)hexanamide, RefChem:201055, GHRP-2 Acetate, h-his-d-trp-ala-trp-d-phe-lys-nh2, orb341840, GTPL1093.
Open PubChem recordClinical trial snapshot
The current ClinicalTrials.gov intervention query for GHRP-6 returns 0 study records. This does not prove efficacy by itself, but it does show whether the peptide is showing up in a formal trial registry rather than only in forums or vendor copy.
No linked intervention records were returned by the current ClinicalTrials.gov query terms for this page.
Literature snapshot
The current PubMed query for GHRP-6 returns 686 results. The articles below are a quick literature surface so the page shows actual papers instead of only generic evidence labels.
Source trail
Each linked source is shown directly so the page can be audited. The page now combines its editorial seed trail with automated official-source enrichment generated on 2026-04-24 from PubChem, ClinicalTrials.gov, PubMed, DailyMed, openFDA label, and Drugs@FDA.